[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617732":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":60,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":26,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Chemical Injection","ACTIVE_COMPARATOR","Local chemical injection at clinician-identified myofascial trigger points.",[13],"Drug: 50\u002F50 Mixture of Lidocaine 1% injection + Bupivacaine 0.25% Injectable Solution",{"label":15,"type":16,"description":17,"interventionNames":18},"Dry Needle","PLACEBO_COMPARATOR","Dry needling at clinician-identified myofascial trigger points.",[19],"Procedure: Dry Needling",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","50\u002F50 Mixture of Lidocaine 1% injection + Bupivacaine 0.25% Injectable Solution","Treatment Group: Receives trigger-point injection with a 50\u002F50 mixture of 1% lidocaine and 0.25% bupivacaine",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"PROCEDURE","Dry Needling","Single session of dry needling to the identified trigger point(s) per protocol.",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Andre Guthrie, BS","CONTACT","3142732556","guthriea@wustl.edu",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Washington University","RECRUITING","St Louis","Missouri","63110","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-90.19789,38.62727,{"lat":51,"lon":50},[54,55,58],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},{"name":56,"role":57,"phone":26,"phoneExt":26,"email":26},"Yong Wang, PhD","PRINCIPAL_INVESTIGATOR",{"name":59,"role":57,"phone":26,"phoneExt":26,"email":26},"Song Hu, PhD",{"type":57,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Yong Wang","Principal Investigator",[64],{"name":65,"class":66},"National Center for Complementary and Integrative Health (NCCIH)","NIH","100617732","multi-modal-imaging-of-myofascial-pain---phase-2-100617732",false,"NCT07322445","Multi-modal Imaging of Myofascial Pain - Phase 2","Development and Identification of Magnetic Resonance, Electrophysiological, and Fiber-optic Imaging Biomarkers of Myofascial Pain","Inclusion Criteria:\n\n1. Adults between the ages of 18 and 80 years old.\n2. History of spontaneous (non-provoked) pain in the neck and\u002For shoulder region lasting at least 3 months. Neck and\u002For shoulder pain, unilateral or bilateral.\n3. Presence of a palpable myofascial trigger point (MTrP) in one or both upper trapezius muscles.\n4. The participant has a Numeric Pain Rating Scale of 4\u002F10 or more in the last one week, and the pain is reproducible by palpating the trigger point.\n5. Pain localized to the area of the trigger point that is reproduced or worsened upon palpation.\n6. Radiation of pain to the head, neck, or face with palpation is allowed but not required.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 or \\>80 years old.\n2. Acute cervical spine pathology, trauma (e.g. whiplash) or cervical radiculopathy\n3. History of surgery involving the head, neck, or shoulder girdle.\n4. Presence of neuromuscular pathologies or inflammatory muscle diseases (e.g. dermatomyositis)\n5. Systemic disease with diffuse body pain (e.g. system lupus erythematosus)\n6. Peripheral neuropathy\n7. Cancer-related pain\n8. Pregnancy, coagulopathy or other bleeding disorder, fever, general\u002Flocal infection at the pain site, substance abuse, or any other diseases that may account for signs and symptoms mimicking myofascial pain.\n9. Contraindication to MRI\n10. Chronic fatigue syndrome, fibromyalgia, or chronic Lyme disease.\n11. Use of acupuncture or changes in pain medications within 6 weeks of enrollment.\n12. Receipt of Botox injection to the neck\u002Fshoulder region within the past 3 months or trigger point injection within the past 6 weeks.","ALL","18 Years","80 Years",{"count":78,"type":79},100,"ESTIMATED","INTERVENTIONAL",[82],"NA","The goal of this study is to evaluate imaging biomarkers for quantitative assessments of myofascial pain and determine their ability to monitor treatment response and predict clinical outcomes.",[85],"Myofascial Pain",[87,88,89],"Magnetic Resonance Imaging","Surface Electromyography","Fiber-optic Imaging and Sensing","2026-01-05",{"date":92,"type":93},"2026-01-07","ACTUAL",{"date":95,"type":93},"2025-10-01",{"date":97,"type":79},"2027-12",{"name":5,"class":6},1]